The Oregon Legislature has passed a bill expanding options for treating severe allergic reactions in schools, allowing stock epinephrine auto-injectors and alternative devices beyond branded EpiPens. The teen-inspired legislation addresses a practical barrier that school nurses and administrators have faced: EpiPen costs that have soared past $600 per two-pack, forcing many schools to choose between stocking the devices and funding other health supplies.

The law reflects a national movement toward epinephrine access reform driven by the reality that anaphylaxis can kill within minutes and schools are where children spend most of their waking hours. Generic auto-injectors and pre-filled syringes cost a fraction of brand-name EpiPens but have been excluded from many school stock-epinephrine programs due to narrow statutory language. Oregon's updated law removes that barrier, giving school districts flexibility to procure the most cost-effective FDA-approved epinephrine delivery devices available.

Oregon healthcare providers — particularly pediatricians, allergists, and family medicine physicians — should update their guidance to families and schools accordingly. The law does not change the clinical standard (epinephrine remains first-line for anaphylaxis), but it does expand the delivery mechanism options that schools can deploy. Prescribers writing school stock-epinephrine orders should familiarize themselves with the alternative devices now permitted. School-based health centers, which operate in over 80 Oregon schools, are well-positioned to train staff on multiple device types. For dental practices that treat pediatric patients, this is a reminder to verify that office anaphylaxis kits are current and that staff are trained on their specific devices.

Watch for the Governor's signature and whether Oregon school districts report meaningful cost savings from switching to generic epinephrine devices in the coming school year.